SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by AspenBio Pharma, Inc. on April 18, 2006. The registrant is incorporated in Colorado. The filing reports on a material event occurring on the same date regarding the resolution of ongoing litigation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement and does not contain financial performance data.
Material Changes
The primary material change reported is the entry into a Settlement Agreement and Release on April 18, 2006, between AspenBio Pharma, Inc. and individuals Roger Hurst and Diane Newman. This agreement resolves litigation between the parties. A press release announcing this settlement was issued on the same date.
Outlook, Risks, and Contingencies
The filing addresses a specific legal contingency by settling the dispute with Hurst and Newman. No forward-looking guidance, management commentary on future operations, or discussion of other risks is included in this document. The settlement agreement is attached as Exhibit 10.1, and the press release is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific financial terms and release conditions within the Settlement Agreement (Exhibit 10.1).
- Review the press release (Exhibit 99.1) for any additional context regarding the litigation history.
- Confirm whether the settlement resolves all outstanding claims between the registrant and the named individuals.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.